US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.93

+0.14500.92%

Volume:68.52K

Turnover:1.09M

Market Cap:3.21B

PE:-19.27

High:15.94

Open:15.92

Low:15.85

Close:15.78

52wk High:15.97

52wk Low:9.84

Shares:201.40M

Float Shares:195.63M

Volume Ratio:0.27

T/O Rate:0.04%

Dividend:1

Dividend Rate:6.28%

EPS(TTM):-0.8265

EPS(LYR):-1.4300

ROE:-4.86%

ROA:2.75%

PB:1.04

PE(LYR):-11.14

Loading ...

Overview Company News Filings

Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Which App to Choose for Stock Account Opening? Ultimate Comparison of Ten Platforms Reveals Top Performer

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Capacity Comparison Among Five Major Power Generation Giants' Flagship Listed Companies

Park Hotels & Resorts schedules first-quarter 2026 earnings conference call

Vivesto Advances Cantrixil With First Dogs Dosed in PK/Toxicology Study

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Press Release: Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Press Release: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

New Fund Offerings Hit 40 This Week with 27 Asset Managers Competing

Press Release: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

AI-Powered Stock Trading Apps in 2026: Sina Finance, Hithink Royalflush, and East Money Lead the Pack

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PK/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":15.925,"timestamp":1787579611965,"preClose":15.78,"halted":0,"volume":68522,"delay":0,"changeRate":0.00918884664131821,"floatShares":195633448,"shares":201398439,"eps":-0.826466,"marketStatus":"Trading","change":0.145,"latestTime":"08-24 09:53:32 EDT","open":15.92,"high":15.935,"low":15.85,"amount":1090067.436248,"amplitude":0.005387,"askPrice":15.94,"askSize":225,"bidPrice":15.92,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-0.826466,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":15.78,"dividendRate":0.062794,"preHourTrading":{"tag":"盘前","latestPrice":15.92,"preClose":15.78,"latestTime":"09:14 EDT","volume":5,"amount":79.6,"timestamp":1787577295690,"change":0.14,"changeRate":0.008872,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":15.78,"preClose":15.78,"latestTime":"19:40 EDT","volume":69452,"amount":1095948.8356,"timestamp":1787355642045,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.27153,"impliedVol":0.2216,"impliedVolPercentile":0.0757},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":195633448,"roa":"2.75%","roe":"-4.86%","lyrEps":-1.43,"volumeRatio":0.27153,"shares":201398439,"dividePrice":1,"high":15.935,"amplitude":0.005387,"preClose":15.78,"low":15.85,"week52Low":9.84,"pbRate":"1.04","psRate":"1.26","week52High":15.965,"institutionHeld":0,"latestPrice":15.925,"committee":-0.948052,"eps":-0.826466,"divideRate":0.062794,"volume":68522,"delay":0,"ttmEps":-0.826466,"open":15.92,"prevYearClose":10.46,"prevWeekClose":15.78,"prevMonthClose":15.06,"prevQuarterClose":14.25,"fiveDayClose":15,"twentyDayClose":15.03,"sixtyDayClose":12.17,"dividendPayoutRate":1.373460620431404,"dividendFrequency":"Q","dividendGrowthYears":0,"dividendGrowthRate":-0.28571428571428564,"fiveYearAvgDividendRate":0.07559574201047665},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"PK","amount":0.25,"announcedDate":"2026-07-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-15","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-15"},{"market":"US","date":"2026-08-06","symbol":"PK","fiscalQuarterEnding":"2026/06","expectedEps":0.57,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":0.7},{"date":"2026-06-30","symbol":"PK","amount":0.25,"announcedDate":"2026-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-30","defaultRemindTime":1782826200000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-15","payableDate":"2026-06-30","currency":"USD","dateTimestamp":1782792000000,"payDate":"2026-07-15"},{"market":"US","date":"2026-04-30","symbol":"PK","fiscalQuarterEnding":"2026/03","expectedEps":0.38,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"post","actualEps":0.45},{"date":"2026-03-31","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-31","defaultRemindTime":1774963800000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-15","payableDate":"2026-03-31","currency":"USD","dateTimestamp":1774929600000,"payDate":"2026-04-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.0556,"hold":0.7222,"sell":0.1111,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7222,"analysts":18,"updateTime":1775620800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2026-08-21","current":-19.093344,"percent":0.217463,"low":-196.066894,"twenty":-46.400028,"median":-5.614856,"eighty":17.858097,"high":55.399897,"avg":-11.346486,"sd":52.706971,"marketCap":3185172380},"quantilePoints":[{"date":"2021-08-27","current":-5.74509,"twenty":-3.546559,"median":12.705805,"eighty":24.987189,"marketCap":4590327091},{"date":"2021-09-03","current":-5.52902,"twenty":-3.565932,"median":12.702277,"eighty":24.944766,"marketCap":4417687278},{"date":"2021-09-10","current":-5.437265,"twenty":-3.571599,"median":12.695796,"eighty":24.807396,"marketCap":4344374481},{"date":"2021-09-17","current":-5.688853,"twenty":-3.581314,"median":12.675381,"eighty":24.746792,"marketCap":4545393441},{"date":"2021-09-24","current":-5.97004,"twenty":-3.589648,"median":12.636863,"eighty":24.72659,"marketCap":4770061692},{"date":"2021-10-01","current":-5.896043,"twenty":-3.599497,"median":12.622139,"eighty":24.665986,"marketCap":4710938468},{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-25","current":9.512373,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2016623108},{"date":"2025-05-02","current":9.559983,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2026716317},{"date":"2025-05-09","current":16.384875,"twenty":-10.159473,"median":-3.675279,"eighty":11.531064,"marketCap":2080879082},{"date":"2025-05-16","current":17.045936,"twenty":-10.159473,"median":-3.674208,"eighty":11.65257,"marketCap":2164833858},{"date":"2025-05-23","current":16.148781,"twenty":-10.159473,"median":-3.6534,"eighty":11.72393,"marketCap":2050895233},{"date":"2025-05-30","current":16.510791,"twenty":-10.159473,"median":-3.629041,"eighty":11.766258,"marketCap":2096870468},{"date":"2025-06-06","current":15.771032,"twenty":-10.159473,"median":-3.604398,"eighty":11.937378,"marketCap":2002921076},{"date":"2025-06-13","current":16.447833,"twenty":-10.159473,"median":-3.588007,"eighty":12.388042,"marketCap":2088874775},{"date":"2025-06-20","current":16.038604,"twenty":-10.162337,"median":-3.578159,"eighty":15.511387,"marketCap":2036902771},{"date":"2025-06-27","current":16.55801,"twenty":-10.162337,"median":-3.568226,"eighty":15.739397,"marketCap":2102867237},{"date":"2025-07-03","current":17.061675,"twenty":-10.162337,"median":-3.549185,"eighty":15.841236,"marketCap":2166832781},{"date":"2025-07-11","current":17.848653,"twenty":-10.162337,"median":-3.540618,"eighty":16.000829,"marketCap":2266778942},{"date":"2025-07-18","current":16.998717,"twenty":-10.162337,"median":-3.507581,"eighty":16.081216,"marketCap":2158837088},{"date":"2025-07-25","current":17.518122,"twenty":-10.162337,"median":-3.495637,"eighty":16.142485,"marketCap":2224801554},{"date":"2025-08-01","current":36.742661,"twenty":-10.162337,"median":-3.456698,"eighty":16.1771,"marketCap":2131074349},{"date":"2025-08-08","current":35.570815,"twenty":-10.162337,"median":-3.417502,"eighty":16.307701,"marketCap":2063107278},{"date":"2025-08-15","current":38.224839,"twenty":-10.162337,"median":-3.417502,"eighty":16.351669,"marketCap":2217040670},{"date":"2025-08-22","current":38.500582,"twenty":-10.162337,"median":-3.417502,"eighty":16.434619,"marketCap":2233033750},{"date":"2025-08-29","current":40.534185,"twenty":-10.162337,"median":-3.417502,"eighty":16.560113,"marketCap":2350982712},{"date":"2025-09-05","current":41.740559,"twenty":-10.1652,"median":-3.433,"eighty":16.629128,"marketCap":2420952436},{"date":"2025-09-12","current":41.361413,"twenty":-10.162337,"median":-3.417502,"eighty":16.709109,"marketCap":2398961952},{"date":"2025-09-19","current":41.809495,"twenty":-10.162337,"median":-3.417502,"eighty":16.776195,"marketCap":2424950706},{"date":"2025-09-26","current":38.914196,"twenty":-10.162337,"median":-3.417502,"eighty":16.947295,"marketCap":2257023369},{"date":"2025-10-03","current":38.224839,"twenty":-10.162337,"median":-3.417502,"eighty":17.03964,"marketCap":2217040670},{"date":"2025-10-10","current":37.052932,"twenty":-10.162337,"median":-3.417502,"eighty":17.090583,"marketCap":2149070082},{"date":"2025-10-17","current":37.501014,"twenty":-10.162337,"median":-3.417502,"eighty":17.354431,"marketCap":2175058836},{"date":"2025-10-24","current":38.466114,"twenty":-10.162337,"median":-3.417502,"eighty":17.59682,"marketCap":2231034615},{"date":"2025-10-31","current":-178.753982,"twenty":-10.172486,"median":-3.448497,"eighty":17.810878,"marketCap":2145047787},{"date":"2025-11-07","current":-169.247209,"twenty":-10.219605,"median":-3.476395,"eighty":17.810878,"marketCap":2030966504},{"date":"2025-11-14","current":-174.244666,"twenty":-10.301936,"median":-3.504298,"eighty":17.810878,"marketCap":2090935987},{"date":"2025-11-21","current":-163.916588,"twenty":-10.6072,"median":-3.538772,"eighty":17.810878,"marketCap":1966999055},{"date":"2025-11-28","current":-180.408196,"twenty":-10.799451,"median":-3.540618,"eighty":17.810878,"marketCap":2164898350},{"date":"2025-12-05","current":-174.577829,"twenty":-11.1402,"median":-3.542049,"eighty":17.810878,"marketCap":2094933953},{"date":"2025-12-12","current":-179.90845,"twenty":-11.860354,"median":-3.542049,"eighty":17.810878,"marketCap":2158901402},{"date":"2025-12-19","current":-180.574778,"twenty":-12.666412,"median":-3.542049,"eighty":17.810878,"marketCap":2166897333},{"date":"2025-12-26","current":-181.074523,"twenty":-12.945597,"median":-3.542049,"eighty":17.810878,"marketCap":2172894281},{"date":"2026-01-02","current":-174.244666,"twenty":-13.160355,"median":-3.542049,"eighty":17.810878,"marketCap":2090935987},{"date":"2026-01-09","current":-185.738817,"twenty":-13.430949,"median":-3.542049,"eighty":17.810878,"marketCap":2228865799},{"date":"2026-01-16","current":-191.402601,"twenty":-13.900553,"median":-3.542049,"eighty":17.810878,"marketCap":2296831214},{"date":"2026-01-23","current":-193.06842,"twenty":-36.411218,"median":-3.542049,"eighty":17.810878,"marketCap":2316821042},{"date":"2026-01-30","current":-181.574269,"twenty":-42.996332,"median":-3.544901,"eighty":17.810878,"marketCap":2178891230},{"date":"2026-02-06","current":-186.07198,"twenty":-44.121622,"median":-3.546973,"eighty":17.810878,"marketCap":2232863765},{"date":"2026-02-13","current":-190.236528,"twenty":-45.253331,"median":-3.546973,"eighty":17.810878,"marketCap":2282838334},{"date":"2026-02-20","current":-190.236528,"twenty":-46.332575,"median":-3.546973,"eighty":17.810878,"marketCap":2282838334},{"date":"2026-02-27","current":-8.333483,"twenty":-46.332575,"median":-3.566587,"eighty":17.810878,"marketCap":2358375720},{"date":"2026-03-06","current":-8.041704,"twenty":-46.332575,"median":-3.581442,"eighty":17.810878,"marketCap":2275802360},{"date":"2026-03-13","current":-7.379865,"twenty":-46.332575,"median":-3.589648,"eighty":17.810878,"marketCap":2088501812},{"date":"2026-03-20","current":-7.481341,"twenty":-46.332575,"median":-3.589648,"eighty":17.810878,"marketCap":2117219505},{"date":"2026-03-27","current":-7.623572,"twenty":-46.332575,"median":-3.632324,"eighty":17.810878,"marketCap":2157470827},{"date":"2026-04-02","current":-7.381779,"twenty":-46.332575,"median":-3.670075,"eighty":17.810878,"marketCap":2089043580},{"date":"2026-04-10","current":-7.950703,"twenty":-46.332575,"median":-4.395912,"eighty":17.810878,"marketCap":2250048866},{"date":"2026-04-17","current":-7.950703,"twenty":-46.332575,"median":-4.654495,"eighty":17.810878,"marketCap":2250048866},{"date":"2026-04-24","current":-7.872476,"twenty":-46.332575,"median":-4.7273,"eighty":17.810878,"marketCap":2227910639},{"date":"2026-05-01","current":-10.736806,"twenty":-46.332575,"median":-4.787552,"eighty":17.810878,"marketCap":2308413282},{"date":"2026-05-08","current":-10.480181,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2253238933},{"date":"2026-05-15","current":-10.208577,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2194844001},{"date":"2026-05-22","current":-10.733054,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2307606629},{"date":"2026-05-29","current":-11.398016,"twenty":-46.392533,"median":-4.816423,"eighty":17.848653,"marketCap":2450573531},{"date":"2026-06-05","current":-13.149396,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2827120163},{"date":"2026-06-12","current":-13.449097,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2891555950},{"date":"2026-06-18","current":-13.580217,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2919746607},{"date":"2026-06-26","current":-13.645776,"twenty":-46.392533,"median":-4.816423,"eighty":17.848653,"marketCap":2933841935},{"date":"2026-07-02","current":-13.27115,"twenty":-46.392533,"median":-4.816423,"eighty":17.848653,"marketCap":2853297201},{"date":"2026-07-10","current":-13.243053,"twenty":-46.392533,"median":-5.159038,"eighty":17.848653,"marketCap":2847256346},{"date":"2026-07-17","current":-13.673873,"twenty":-46.392533,"median":-5.361788,"eighty":17.848653,"marketCap":2939882791},{"date":"2026-07-24","current":-13.664508,"twenty":-46.392533,"median":-5.472783,"eighty":17.848653,"marketCap":2937869172},{"date":"2026-07-31","current":-14.104694,"twenty":-46.400028,"median":-5.505341,"eighty":17.858097,"marketCap":3032509235},{"date":"2026-08-07","current":-17.727254,"twenty":-46.400028,"median":-5.52902,"eighty":17.858097,"marketCap":2889542332},{"date":"2026-08-14","current":-18.565123,"twenty":-46.400028,"median":-5.558619,"eighty":17.858097,"marketCap":3026115099},{"date":"2026-08-21","current":-19.540935,"twenty":-46.400028,"median":-5.614856,"eighty":17.858097,"marketCap":3185172380}],"updateTime":1787556266740},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621622530","title":"Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2621622530","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621622530?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:27","pubTimestamp":1774355230,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics (HOTH) reported “positive” pharmacokinetic – or PK -, safety, and clinical activity data for HT-001, demonstrating a ~77% increas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-ht-001-shows-positive-pk-safety-and-clinical-activity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-ht-001-shows-positive-pk-safety-and-clinical-activity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4181","HOTH","BK4218","PK","HT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621809037","title":"Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621809037","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621809037?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:32","pubTimestamp":1774323120,"startTime":"0","endTime":"0","summary":"Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer. SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positivetopline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin  in adult patients with advanced non-squamous non-small cell lung cancer .SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 study conducted in 625 patients across 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive HD204 or Avastin in combination with standard chemotherapy.\"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies,\" said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma. \"Our experience with HD204 supports the view that well-designed development programs can reliably anticipate cl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab-302722770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","PFS","BK4195","ORR","BK4181","BK7095","OS","BK4007","ORR.AU","BK4097","BK4218","PBH","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429292","title":"Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429292","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429292?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919800,"startTime":"0","endTime":"0","summary":"-- Promising Phase 2a data announced for izicopan, underscoring its. potential as a meaningfully differentiated, effective and safe oral. -- Substantial progress made toward Phase 2b readiness for izicopan in. -- InflaRx actively reviewing and considering additional development in. its potential in HS, AAV and select additional I&I indications. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: \"With the strong Phase 2a results reported in hidradenitis suppurativa and chronic spontaneous urticaria, and its best-in-class potential, we made the strategic decision to focus our resources on izicopan. We are in active discussions with the FDA for the design of our Phase 2b trial in HS and look forward to establishing a clear path forward soon. By tightly focusing the Company on izicopan in select inflammation and immunology indications, we believe we are well positioned to advance to the next stage of development and effectively execute our plans.\". Complete Pha","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","SG9999014559.SGD","LU0237698245.USD","IE000M9KFDE8.USD","SG9999015341.SGD","IE00BLSP4239.USD","LU0320765646.SGD","LU1868837300.USD","IE00B3T34201.USD","PK","SG9999014542.SGD","SG9999002224.SGD","LU1868837136.USD","LU1868836591.USD","LU1868836757.USD","BK4504","LU0061475181.USD","IFRX","SG9999014575.USD","LU0640476718.USD","LU0942090050.USD","BK4181","LU2552382058.USD","LU2129689514.USD","LU2552382132.HKD","LU0689626769.HKD","BK4558","IE00B1XK9C88.USD","LU0323591593.USD","SG9999002232.USD","LU0234572021.USD","BK4139","IE00BN8TJ469.HKD","GB00BDT5M118.USD","BK4559","IE00BWXC8680.SGD","LU0868494708.USD","LU1430594728.SGD","LU1914381329.SGD","LU0868494617.USD","IE00BLSP4452.SGD","BK4567","LU2097829019.USD","LU2552382215.SGD","LU1280957306.USD","LU2129689431.USD","BK4585","PG","LU2242652126.USD","LU0094547139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187175653","title":"Which App to Choose for Stock Account Opening? Ultimate Comparison of Ten Platforms Reveals Top Performer","url":"https://stock-news.laohu8.com/highlight/detail?id=1187175653","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187175653?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:21","pubTimestamp":1773901316,"startTime":"0","endTime":"0","summary":"For novice investors, selecting the right application is the crucial first step in opening a stock trading account. Among the ten mainstream platforms in the market, including Flush, East Money, Sina...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","SINA","BK4218","BK4588","BK4585","VGT","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620595255","title":"Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620595255","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620595255?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":"- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March  18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258004/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2-Trial-of-Bosakitug-ATI-045-in-Atopic-Dermatitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BSA","IE00B19Z4B17.USD","BK4187","BK4006","TSLP","ATI","LU0963586101.USD","LU1169590202.USD","BK4007","BK4181","IGA","LU1878469433.USD","EASI","PD","BK4023","PK","LU1169589451.USD","IE00B66KJ199.SGD","IE0031619046.USD","LU2065731478.USD","IE00B7SZL793.SGD","BK4132","AD","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620226234","title":"Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226234","media":"GlobeNewswire","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:05","pubTimestamp":1773828300,"startTime":"0","endTime":"0","summary":"The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in foc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3257984/0/en/Ovid-Therapeutics-Announces-New-OV329-Data-and-Indication-Expansion-Phase-1-Clearance-for-OV4071-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","TGA","BK4218","BK4539","BK4585","IE00B19Z3B42.SGD","IE0002270589.USD","BK4181","LU1093756325.SGD","IS","BK4007","LENZ","BK4097","AES","BK4519","IE00B7SZLL34.SGD","LU1093756168.USD","LU0061475181.USD","BK4213","BK4588","IE00B19Z3581.USD","BK4139","BK4105","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116988105","title":"Capacity Comparison Among Five Major Power Generation Giants' Flagship Listed Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1116988105","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116988105?lang=en_us&edition=fundamental","pubTime":"2026-03-14 20:41","pubTimestamp":1773492075,"startTime":"0","endTime":"0","summary":"The five flagship listed companies of China's major power generation groups—GD Power, Huaneng Power International, Huadian Power International, China Power International Development, and Datang...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619102641","title":"Park Hotels & Resorts schedules first-quarter 2026 earnings conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2619102641","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619102641?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:16","pubTimestamp":1773432970,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts schedules first-quarter 2026 earnings conference call               Park Hotels & Resorts plans to report first-quarter 2026 financial results after the stock market closes on Ap","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5t78RS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619016480","title":"Vivesto Advances Cantrixil With First Dogs Dosed in PK/Toxicology Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2619016480","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619016480?lang=en_us&edition=fundamental","pubTime":"2026-03-13 15:43","pubTimestamp":1773387819,"startTime":"0","endTime":"0","summary":"An update from Vivesto AB ( ($SE:VIVE) ) is now available. Vivesto AB has initiated dosing of the first dogs in a pharmacokinetic and toxicology st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivesto-advances-cantrixil-with-first-dogs-dosed-in-pk-toxicology-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivesto-advances-cantrixil-with-first-dogs-dosed-in-pk-toxicology-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0348788117.USD","LU2008162690.USD","LU2152927971.USD","SG9999002414.USD","BK4548","LU0499858602.USD","SG9999014492.USD","SG9999013460.SGD","SGXZ58947870.SGD","LU2045819591.USD","LU2125910849.SGD","LU0516422366.SGD","LU1861220207.SGD","LU0210637038.USD","LU2238330802.EUR","LU0532188223.SGD","BK4566","BK4581","BK4181","LU0072462343.USD","BK4585","BK4588","LU0441851309.USD","LU0516423091.SGD","SG9999001135.SGD","LU0589944569.HKD","LU1770036033.HKD","LU1242518931.SGD","IE0031814969.USD","LU1242518857.USD","PK","SG9999002604.SGD","LU0516423174.USD","LU2065171311.SGD","LU2177674079.SGD","LU1861217088.USD","SG9999005177.SGD","SG9999013486.USD","LU0175139822.USD","BK4551","LU0264606111.USD","LU0823038988.USD","LU0572940350.SGD","LU0289960550.SGD","LU0572939691.SGD","LU0516422952.EUR","BK4218","SG9999014484.SGD","LU0261945553.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619152745","title":"OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619152745","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619152745?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:05","pubTimestamp":1773345900,"startTime":"0","endTime":"0","summary":"-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations  -- Next-generation PI3Kα pan-mutant inhibitor developme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3255093/0/en/OnKure-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4218","BK4181","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619085152","title":"Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619085152","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619085152?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:01","pubTimestamp":1773345660,"startTime":"0","endTime":"0","summary":"Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3255076/0/en/Erasca-Reports-Fourth-Quarter-and-Full-Year-2025-Business-Updates-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4181","BK4218","ERAS","PK","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618907060","title":"Press Release: Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618907060","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618907060?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:00","pubTimestamp":1773295200,"startTime":"0","endTime":"0","summary":"-- Full year 2025 total revenues increased by 27% to US$376.1 million,driven by continued growth of RUCONEST and rising demand for Joenja. fourth quarter revenue increased by 9% to US$86.7 million. -- Joenja revenue increased by 29% to US$58.2 million and fourth quarter. growth), driven by significant and accelerating growth for Joenja and. \"2025 was a defining year for Pharming and reflects the focus and discipline our teams have brought to executing our strategy. We outperformed revenue guidance and delivered strong financial performance, with total revenues up 27%, driven by continued RUCONEST growth and rising demand for Joenja .Building on this momentum, we plan to further enhance capital allocation to drive growth. We expect 2026 total revenues in the range of US$405 million to US$425 million, representing 8% to 13% growth, driven by both Joenja and RUCONEST.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EEA","LU0128526141.USD","LU1815336091.USD","EMA","PK","PHAR","BK4585","BK4588","BK4181","BK4232","BK4022","MAA","BK4215","LU0029874061.USD","CRL","LU0757428866.USD","LU0390134368.USD","BK4139","BK4530","BK4087","BK4121","R","CHMP","IE00BFMHRM44.USD","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618941435","title":"Press Release: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941435?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:30","pubTimestamp":1773228600,"startTime":"0","endTime":"0","summary":"Completed Phase 1 pharmacokinetic  clinical trial of denifanstat and resmetirom combination. Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredients . First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing. Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis. \"2025 saw important advances in both our MASH and acne programs,\" said David Happel, Chief Executive Officer of Sagimet. \"We completed our Phase 1 PK clinical trial of denifanstat and resmetirom combination and anticipate advancing the combination into a proof-of-concept Phase 2 clinical trial in F4 MASH, for which there are currently no approved treatments, in the second half of the year. In acne, positive 52-week data from our license partner Ascletis' Phase 3 open-label acne trial with denifanstat will support Ascletis' NDA that was accepted","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DDI","BK4181","PK","SGMT","00511","API","BK4218","BK4551","R","BK4022","BK4085","BK4232","BK4535","BK4503","BK4023","BK1145","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618495822","title":"Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618495822","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618495822?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:45","pubTimestamp":1773146700,"startTime":"0","endTime":"0","summary":"A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to ClinicMELBOURNE, Australia, March  10, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252839/0/en/Propanc-Biopharma-Executes-Service-Agreement-with-FyoniBio-to-Establish-Validate-Pharmacokinetics-Assay-for-Phase-1b-First-In-Human-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","PK","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930858","title":"Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930858","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930858?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update.\"We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence. The progress we've made, especially with our postpartum depression therapeutic, LPCN 1154, demonstrates the strength of our science and our team's commitment to delivering more effective treatments for patients in need,\" said Dr Mahesh Patel, Lipocine President and CEO. \"We're excited about the near-term milestones ahead and remain committed to advancing our pipeline proficiently.\". -- Lipocine is developing LPCN 1154, a rapid onset, short treatment duration. oral product candidate comprising the neuroactive steroid brexanolone for. -- The last patient completed the fina","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4519","BK4099","BK4530","IE00B7SZLL34.SGD","LU1093756168.USD","BK4188","LU0061475181.USD","BK4563","BK4561","BK4585","BK4081","BK4555","ASM","BK4181","BK4604","GCC","AES","LU1093756325.SGD","BK4588","BK4171","BK4121","03160","DRE","LPCN","BK4105","BK4218","PK","PPD","IE00B19Z3581.USD","TM","IE00B19Z3B42.SGD","BK4007","PAM","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930683","title":"SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930683","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930683?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:31","pubTimestamp":1773142260,"startTime":"0","endTime":"0","summary":"Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March  10, 2026  (GLOB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252675/0/en/SAB-BIO-Announces-Additional-Phase-1-Data-for-SAB-142-in-Adult-Patients-with-Established-Autoimmune-Type-1-Diabetes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4218","LU1169589451.USD","BK4023","PK","BK4121","BK4585","LU1169590202.USD","BIO","BK4181","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168538631","title":"New Fund Offerings Hit 40 This Week with 27 Asset Managers Competing","url":"https://stock-news.laohu8.com/highlight/detail?id=1168538631","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168538631?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:50","pubTimestamp":1773139852,"startTime":"0","endTime":"0","summary":"This week saw the launch of 40 new funds from 27 asset management companies, including E Fund Management, Fullgoal Fund, China Merchants Fund, Tianhong Fund, Southern Asset Management, Invesco Great...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4218","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618390674","title":"Press Release: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618390674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618390674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:05","pubTimestamp":1773086700,"startTime":"0","endTime":"0","summary":"Compelling Phase 1 Data for SEP-631  in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria  in Second Half of 2026. Advancing SEP-479  Toward Phase 1 Initiation in First Half of 2026. Cash Runway Expected to Support Operating Plans at Least into 2029. SOUTH SAN FRANCISCO, Calif., March 09, 2026  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","LU1169590202.USD","PD","BK4022","LU1169589451.USD","BK4007","BK4232","LU2065732104.USD","BK4599","BK4181","R","GPCR","BK4218","SEPN","BK4023","BK4097","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617680733","title":"Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680733?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802000,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., March 06, 2026  --  Adial Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025.-- Achieved positive clinical study results from the AD04-103. -- Received a positive response from the U.S. Food and Drug. core assets and extend international exclusivity by 14 years. supply in support of late-stage development and future. \"2025 was a pivotal year for Adial as we continued to advance AD04 scientifically, strategically, and within an evolving regulatory landscape,\" said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. \"Our positive AD04-103 pharmacokinetic results, productive End-of-Phase 2 meeting with the FDA, and supportive FDA feedback on our in vitro bridging strategy provided meaningful validation of our clinical and regul","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCT","BK4007","BK4090","ADIL","PK","BK4181","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110539111","title":"AI-Powered Stock Trading Apps in 2026: Sina Finance, Hithink Royalflush, and East Money Lead the Pack","url":"https://stock-news.laohu8.com/highlight/detail?id=1110539111","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110539111?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:24","pubTimestamp":1772713441,"startTime":"0","endTime":"0","summary":"As the digital transformation of securities firms concluded in 2025 and stricter regulatory policies took hold, AI technology has deeply penetrated the stock trading software sector. Investor demands...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK0201","LU2097828557.USD","BK4181","300033","LU2097828474.EUR","LU1981816686.USD","LU2495084118.USD","SG9999001051.SGD","BK0077","BK0272","PK","BK0028","LU2097828714.EUR","LU2148510915.USD","LU1997245177.USD","LU2097828805.USD","SG9999002950.SGD","BK0188","LU1064130708.USD","BK4588","LU2097828631.EUR","LU2580892789.USD","300059","LU1831875114.USD","BK0187","SG9999001093.SGD","159819","BK0012","SINA","BK4585","VGT","LU1997244956.HKD","BK0055","LU0326950275.SGD","LU1997245094.SGD","BK0196","SG9999001069.SGD","LU2580892862.HKD","SG9999014674.SGD","LU2289578879.USD","BK0276","LU1064131003.USD","BK0095"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":171,"code":"91000000","status":"200"}]}}